摘要
骨髓增生异常综合征(myelodysplastic syndrome, MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病,随着表观遗传学的深入研究,发现DNA异常甲基化在MDS的整个疾病过程中起着重要作用。地西他滨(decitabine, DAC)作为去甲基化药物的代表性药物,目前已经广泛应用于MDS的治疗中,本文就DAC在MDS治疗中的应用进展做一综述。
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid clonal diseases originating from hematopoietic stem cells. With the in-depth study of epigenetics, it has been found that abnormal DNA methylation plays an important role in the whole disease process of MDS. Decitabine (DAC), as a representative hypomethylating agent, has been widely used in the treatment of MDS. This article reviews the application progress of DAC in the treatment of MDS.
出处
《临床医学进展》
2024年第5期73-78,共6页
Advances in Clinical Medicine
